These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 11113067)
1. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Schreiber S; Fedorak RN; Nielsen OH; Wild G; Williams CN; Nikolaus S; Jacyna M; Lashner BA; Gangl A; Rutgeerts P; Isaacs K; van Deventer SJ; Koningsberger JC; Cohard M; LeBeaut A; Hanauer SB Gastroenterology; 2000 Dec; 119(6):1461-72. PubMed ID: 11113067 [TBL] [Abstract][Full Text] [Related]
2. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Fedorak RN; Gangl A; Elson CO; Rutgeerts P; Schreiber S; Wild G; Hanauer SB; Kilian A; Cohard M; LeBeaut A; Feagan B Gastroenterology; 2000 Dec; 119(6):1473-82. PubMed ID: 11113068 [TBL] [Abstract][Full Text] [Related]
3. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. van Deventer SJ; Elson CO; Fedorak RN Gastroenterology; 1997 Aug; 113(2):383-9. PubMed ID: 9247454 [TBL] [Abstract][Full Text] [Related]
4. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Khanna R; Preiss JC; MacDonald JK; Timmer A Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human interleukin 10 for induction of remission in Crohn's disease. Buruiana FE; Solà I; Alonso-Coello P Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD005109. PubMed ID: 21069683 [TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Sands BE; Winston BD; Salzberg B; Safdi M; Barish C; Wruble L; Wilkins R; Shapiro M; Schwertschlag US; Aliment Pharmacol Ther; 2002 Mar; 16(3):399-406. PubMed ID: 11876692 [TBL] [Abstract][Full Text] [Related]
7. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. van der Woude CJ; Stokkers P; van Bodegraven AA; Van Assche G; Hebzda Z; Paradowski L; D'Haens G; Ghosh S; Feagan B; Rutgeerts P; Dijkstra G; de Jong DJ; Oldenburg B; Farhan M; Richard T; Dean Y; Hommes DW; Inflamm Bowel Dis; 2010 Oct; 16(10):1708-16. PubMed ID: 20848453 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Rutgeerts P; D'Haens G; Targan S; Vasiliauskas E; Hanauer SB; Present DH; Mayer L; Van Hogezand RA; Braakman T; DeWoody KL; Schaible TF; Van Deventer SJ Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056 [TBL] [Abstract][Full Text] [Related]
9. Low dose naltrexone for induction of remission in Crohn's disease. Segal D; Macdonald JK; Chande N Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033 [TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. Eser A; Colombel JF; Rutgeerts P; Vermeire S; Vogelsang H; Braddock M; Persson T; Reinisch W Inflamm Bowel Dis; 2015 Oct; 21(10):2247-53. PubMed ID: 26197451 [TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. Angel JB; Jacobson MA; Skolnik PR; Giordano M; Shapiro L; LeBeaut A; Greaves W; Fuchs AC AIDS; 2000 Nov; 14(16):2503-8. PubMed ID: 11101061 [TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. Carreño V; Zeuzem S; Hopf U; Marcellin P; Cooksley WG; Fevery J; Diago M; Reddy R; Peters M; Rittweger K; Rakhit A; Pardo M J Hepatol; 2000 Feb; 32(2):317-24. PubMed ID: 10707873 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Tilg H; van Montfrans C; van den Ende A; Kaser A; van Deventer SJ; Schreiber S; Gregor M; Ludwiczek O; Rutgeerts P; Gasche C; Koningsberger JC; Abreu L; Kuhn I; Cohard M; LeBeaut A; Grint P; Weiss G Gut; 2002 Feb; 50(2):191-5. PubMed ID: 11788558 [TBL] [Abstract][Full Text] [Related]
15. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ; Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865 [TBL] [Abstract][Full Text] [Related]
16. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Colombel JF; Rutgeerts P; Malchow H; Jacyna M; Nielsen OH; Rask-Madsen J; Van Deventer S; Ferguson A; Desreumaux P; Forbes A; Geboes K; Melani L; Cohard M Gut; 2001 Jul; 49(1):42-6. PubMed ID: 11413109 [TBL] [Abstract][Full Text] [Related]
18. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339 [TBL] [Abstract][Full Text] [Related]
19. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Hommes DW; Mikhajlova TL; Stoinov S; Stimac D; Vucelic B; Lonovics J; Zákuciová M; D'Haens G; Van Assche G; Ba S; Lee S; Pearce T Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585 [TBL] [Abstract][Full Text] [Related]
20. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Lichtenstein GR; Yan S; Bala M; Hanauer S Am J Gastroenterol; 2004 Jan; 99(1):91-6. PubMed ID: 14687148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]